Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Articles
Page 2 of 38
-
Citation: Journal of Hematology & Oncology 2023 16:95
-
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not s...
Citation: Journal of Hematology & Oncology 2023 16:94 -
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immuno...
Citation: Journal of Hematology & Oncology 2023 16:93 -
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy...
Citation: Journal of Hematology & Oncology 2023 16:92 -
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
TP53 mutations (TP53MT) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly le...
Citation: Journal of Hematology & Oncology 2023 16:91 -
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to...
Citation: Journal of Hematology & Oncology 2023 16:90 -
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
RNA modification has recently become a significant process of gene regulation, and the methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification, methylating various types of ...
Citation: Journal of Hematology & Oncology 2023 16:89 -
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase ...
Citation: Journal of Hematology & Oncology 2023 16:88 -
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions
NEDDylation, a post-translational modification through three-step enzymatic cascades, plays crucial roles in the regulation of diverse biological processes. NEDD8-activating enzyme (NAE) as the only activation...
Citation: Journal of Hematology & Oncology 2023 16:87 -
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approva...
Citation: Journal of Hematology & Oncology 2023 16:86 -
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the ...
Citation: Journal of Hematology & Oncology 2023 16:85 -
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis
Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the infl...
Citation: Journal of Hematology & Oncology 2023 16:84 -
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least another one directed against an activating receptor in immune effector cells: CD3 for recrui...
Citation: Journal of Hematology & Oncology 2023 16:83 -
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at risk for reduced survival vers...
Citation: Journal of Hematology & Oncology 2023 16:82 -
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Citation: Journal of Hematology & Oncology 2023 16:81 -
Metabolism, metabolites, and macrophages in cancer
Tumour-associated macrophages (TAMs) are crucial components of the tumour microenvironment and play a significant role in tumour development and drug resistance by creating an immunosuppressive microenvironmen...
Citation: Journal of Hematology & Oncology 2023 16:80 -
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalat...
Citation: Journal of Hematology & Oncology 2023 16:79 -
Novel target and treatment agents for natural killer/T-cell lymphoma
The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL), which in turn has revolutionized the tre...
Citation: Journal of Hematology & Oncology 2023 16:78 -
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
The receptor tyrosine kinases TAM family (TYRO3, AXL, and MERTK) are highly expressed in multiple forms of cancer cells and tumor-associated macrophages and promote the development of cancers including pancrea...
Citation: Journal of Hematology & Oncology 2023 16:77 -
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Survival in multiple myeloma has improved significantly in recent years, especially in young patients. We reviewed the evolution of the survival of patients with MM in three groups based on age at MM diagnosis...
Citation: Journal of Hematology & Oncology 2023 16:76 -
Clinical development of mRNA therapies against solid tumors
The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to ...
Citation: Journal of Hematology & Oncology 2023 16:75 -
Advances of medical nanorobots for future cancer treatments
Early detection and diagnosis of many cancers is very challenging. Late stage detection of a cancer always leads to high mortality rates. It is imperative to develop novel and more sensitive and effective diag...
Citation: Journal of Hematology & Oncology 2023 16:74 -
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest s...
Citation: Journal of Hematology & Oncology 2023 16:73 -
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
The treatment landscape for chronic lymphocytic leukemia (CLL) continues to undergo considerable evolution. Optimal selection of initial therapy from multiple effective options provides a major challenge for c...
Citation: Journal of Hematology & Oncology 2023 16:72 -
Tumor-associated myeloid cells in cancer immunotherapy
Tumor-associated myeloid cells (TAMCs) are among the most important immune cell populations in the tumor microenvironment, and play a significant role on the efficacy of immune checkpoint blockade. Understandi...
Citation: Journal of Hematology & Oncology 2023 16:71 -
A gene signature can predict risk of MGUS progressing to multiple myeloma
Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients into clinical risk groups. A molecular signature predicting...
Citation: Journal of Hematology & Oncology 2023 16:70 -
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for...
Citation: Journal of Hematology & Oncology 2023 16:69 -
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity agai...
Citation: Journal of Hematology & Oncology 2023 16:68 -
Exosomal circRNA: emerging insights into cancer progression and clinical application potential
Exosomal circRNA serves a novel genetic information molecule, facilitating communication between tumor cells and microenvironmental cells, such as immune cells, fibroblasts, and other components, thereby regul...
Citation: Journal of Hematology & Oncology 2023 16:67 -
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence...
Citation: Journal of Hematology & Oncology 2023 16:66 -
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Hematologic malignancies (HMs) pose a serious threat to patients’ health and life, and the five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis and the complex clinical ...
Citation: Journal of Hematology & Oncology 2023 16:65 -
Small RNA modifications: regulatory molecules and potential applications
Small RNAs (also referred to as small noncoding RNAs, sncRNA) are defined as polymeric ribonucleic acid molecules that are less than 200 nucleotides in length and serve a variety of essential functions within ...
Citation: Journal of Hematology & Oncology 2023 16:64 -
A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer
Early detection is critical for improving the survival of breast cancer (BC) patients. Exhaled breath testing as a non-invasive technique might help to improve BC detection. However, the breath test accuracy f...
Citation: Journal of Hematology & Oncology 2023 16:63 -
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells
The cytotoxicity of NK cells is largely dependent on IgG Fc receptor CD16a, which mediates antibody-dependent cell-mediated cytotoxicity (ADCC). The high-affinity and non-cleavable CD16 (hnCD16) is developed a...
Citation: Journal of Hematology & Oncology 2023 16:62 -
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
Citation: Journal of Hematology & Oncology 2023 16:61 -
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue att...
Citation: Journal of Hematology & Oncology 2023 16:60 -
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy
Amino acids are basic nutrients for immune cells during organ development, tissue homeostasis, and the immune response. Regarding metabolic reprogramming in the tumor microenvironment, dysregulation of amino a...
Citation: Journal of Hematology & Oncology 2023 16:59 -
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide ...
Citation: Journal of Hematology & Oncology 2023 16:58 -
Gastric cancer treatment: recent progress and future perspectives
Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate of regular screening. Systemi...
Citation: Journal of Hematology & Oncology 2023 16:57 -
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018
Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked elect...
Citation: Journal of Hematology & Oncology 2023 16:56 -
The artificial intelligence and machine learning in lung cancer immunotherapy
Since the past decades, more lung cancer patients have been experiencing lasting benefits from immunotherapy. It is imperative to accurately and intelligently select appropriate patients for immunotherapy or p...
Citation: Journal of Hematology & Oncology 2023 16:55 -
Cancer cachexia: molecular mechanisms and treatment strategies
Muscle wasting is a consequence of physiological changes or a pathology characterized by increased catabolic activity that leads to progressive loss of skeletal muscle mass and strength. Numerous diseases, inc...
Citation: Journal of Hematology & Oncology 2023 16:54 -
Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhib...
Citation: Journal of Hematology & Oncology 2023 16:53 -
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
Citation: Journal of Hematology & Oncology 2023 16:52 -
Correction: A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1
Citation: Journal of Hematology & Oncology 2023 16:51 -
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-l...
Citation: Journal of Hematology & Oncology 2023 16:50 -
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate ther...
Citation: Journal of Hematology & Oncology 2023 16:49 -
Echinomycin as a promising therapeutic agent against KSHV-related malignancies
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL), which preferentially arise in immunocompromi...
Citation: Journal of Hematology & Oncology 2023 16:48 -
Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization
COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4/5 after the primary 2-dose and booster vaccination remained unkno...
Citation: Journal of Hematology & Oncology 2023 16:47 -
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis
Bone metastasis is the leading cause of death in patients with prostate cancer (PCa) and currently has no effective treatment. Disseminated tumor cells in bone marrow often obtain new characteristics to cause ...
Citation: Journal of Hematology & Oncology 2023 16:46
-
Official journal of
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
2022 Citation Impact
28.5 - 2-year Impact Factor
23.1 - 5-year Impact Factor
4.045 - SNIP (Source Normalized Impact per Paper)
6.046 - SJR (SCImago Journal Rank)2023 Speed
5 days submission to first editorial decision for all manuscripts (Median)
59 days submission to accept (Median)2023 Usage
3,173,795 downloads
2,671 Altmetric mentions
On the blog
-
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).